[A23-115] Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2024
Project no.:
A23-115
Commission:
Commission awarded on 29.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with advanced non-small cell lung cancer whose tumours have an activating human epidermal growth factor receptor 2 mutation
Result of dossier assessment:
- Following prior treatment with platinum-based chemotherapy without immunotherapy: added benefit not proven
- Following prior treatment with a PD-1/PD-L1 antibody in combination with platinum-based chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-based chemotherapy: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://dx.doi.org/10.60584/A23-115_en
| Project no. | Title | Status |
|---|---|---|
| A23-07 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-08 | Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-80 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-81 | Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V | Commission completed |